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In two recent issues of New England Journal of Medicine,
studies using hypothermia in patients following cardiac arrest
(CA) to improve neurologic outcome were presented and
debated [1–8]. Not a new issue, having first surfaced in the
1950s [9,10], hypothermia as a treatment strategy is
potentially promising as a mechanism to curtail neurologic
injury in specific, although not fully defined, patient situations.
As resuscitative measures have expanded, the need for
options to improve neurologic function after CA is of
paramount importance. Two recent trials reported by Holzer
and colleagues [1] (conducted in Europe) and Bernard and
coworkers [2] (conducted in Australia) yielded statistically
significant, positive outcomes (Table 1). Our goals in the
present commentary are to affirm the viability of hypothermia
as a therapeutic intervention, to evaluate the European and
Australian trials, and to explore the potential of hypothermia
as a treatment modality.
Hypothermia: the science
Data support the contention that hypothermia is not only
biologically plausible as a therapy but also improves
neurologic outcome in animals and, now, in humans [1,2,11].
The timing and duration of treatment, as well as the degree of
hypothermia, were shown to impact on efficacy and outcome
[12,13]. Given different mechanistic etiologies for neurologic
injury, different diseases have been shown to respond
variably to treatment with hypothermia [11,14]. Finally, use of
mild hypothermia has refuted the previously expected side-
effect profile of hypothermia [6,7,11].
The basis for the use of hypothermia in cerebral protection
(i.e. to attenuate the effects of cerebral ischemia) is
supported by animal studies. Cerebral ischemia causes early
and late effects. Energy failure, ion pump failure, and release
of free radicals and excitotoxic agents occur early, whereas
inflammatory mechanisms and release of stress-related
proteins progress over hours after reperfusion. Excitotoxicity
and free radical formation promote cell damage in ischemic
tissue early after reperfusion. Glutamate levels – a major
component of the excitotoxic response – decrease during
hypothermic treatment of ischemia in rabbits [15]. By
attenuating release of glutamate, the ‘death funnel’ of
N-methyl-D-aspartate receptor stimulation (opening ion
channels, allowing influx of calcium, and thereby producing
the cascade of second messengers that activate kinases and
proteases, leading to cellular destruction) is lessened [16].
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Abstract
Hypothermia as a protectant of neurologic function in the treatment of cardiac arrest patients, although
not a new concept, is now supported by two recent randomized, prospective clinical trials. The basic
science research in support of the effects of hypothermia at the cellular and animal levels is extensive.
The process of cooling for cerebral protection holds potential promise for human resuscitation efforts in
multiple realms. It appears that, at least, those patients who suffer a witnessed cardiac arrest with
ventricular fibrillation and early restoration of spontaneous circulation, such as those who were included
in the European and Australian trials (discussed here), should be considered for hypothermic therapy.
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Later responses to reperfusion following ischemia include
the production of stress-related proteins, such as heat
shock proteins. These proteins, in turn, are believed to
influence other gene products. Elevations in heat shock
protein-70 in the hippocampus are blunted by
hypothermia [17]. Additionally, arachidonic acid products
may be involved in an inflammatory cascade, affecting cell
survival. In gerbils, hypothermia decreases levels of
leukotriene B4 [18] – a substance linked to cerebral
edema.
Safar and Leonov, along with their research groups,
conducted elegent animal studies in the 1980s and 1990s
[11], verifying improvement in outcome when hypothermia is
used as treatment in cardiac arrest models, both with
functional ratings and electromyographic improvement.
Weinrauch and colleagues [19] demonstrated that
hypothermia to 30° and 34°C, achieved by a combination of
partial bypass flow and surface cooling performed
immediately after cardiac arrest, improves both neurologic
deficit score and histologic damage scores in dogs [19].
Table 1
Comparison of two recent trials of hypothermia in cardiac arrest
Trial
Study information and 
statistical significance European [1] Australian [2]
Type of study Randomized: normothermia versus hypothermia Randomized: normothermia versus hypothermia
Multicentered, with nine centers in five countries Four accepting emergency departments
Blinded outcome Not blinded for treatment or outcome
Number of patients 275 Total 77 Total
138 Normothermia 34 Normothermia
137 Hypothermia 43 Hypothermia
Criteria Inclusion Witnessed arrest Initial rhythm VF
Arrest secondary to VF Continued coma after ROSC
Age 18–75 years Age: women >50 years; men >18 years
<60 min to ROSC
Exclusion Temp <30°C Cardiogenic shock (SBP <90 mmHg despite 
Coagulopathy epinephrine)
Pregnant Pregnant
Awake before randomization Other causes of coma
MAP <60 mmHg for >30 min ICU bed unavailable
Hypoxemia for >15 min
Terminal illness
Unavailable for follow-up
Enrolment in other study
Comparability of hypothermia and  The normothermia group had higher rates of  The normothermia group had a higher percentage of 
normothermia groups coronary artery disease and diabetes mellitus bystander-performed cardiopulmonary resuscitation
Cooling Temperature used 32–34°C (bladder temperature) 33°C
Mechanism Cool air circulating device and ice packs Ice packs
Time to start Mean 105 min Cooling began prehospital at a rate of 0.9°C/hour
Duration 24 hours 12 hours
Rewarming Passive over 8 hours Passive
Side effects  No statistical difference between the two groups No statistical difference between the two groups
End-points Primary Favorable neurologic outcome at 6 months  Discharge to home or rehabilitation
after arrest
Secondary (1) Mortality within 6 months  Side effects of hemodynamic, biochemical, 
(2) Complications within 7 days or hematological instability
Outcomes Hypothermia: favorable outcome in  Hypothermia: favorable outcome in 
75 patients (55%) 21 patients (49%)
Normothermia: favorable outcome in  Normothermia: favorable outcome in 
54 patients (39%) 9 patients (26%)
Statistical significance of the outcomes P = 0.009 P = 0.046
The table summarizes some of the features of the two recent studies that examined the neuroprotective advantage of hypothermia in treatment of
cardiac arrest. ICU, intensive care unit; ROSC, restoration of spontaneous circulation; VF, ventricular fibrillation.Hypothermia begun hours after the initial insult is not likely to
affect the initial ischemic processes. Thus, early hypothermia
is likely to be more effective than delayed hypothermia. In a
rat model, delays of 15 min and 30 min preserved the
beneficial effect of hypothermia, but with delays of 45 min
there was no attenuation of infarct volume [12]. In dogs,
delaying hypothermia by 15 min obscured the benefit in
functional outcome as compared with that with immediate
hypothermia [13]; however, it might have attenuated tissue
damage, as detected histologically. In addition to initiation
timing, duration has been investigated. Increasing the
duration of hypothermia appears to decrease infarct size
[12]. In a rat model, hypothermia with durations of 3 and
4 hours was superior to 2 hours in terms of effect on infarct
volume, whereas 1 hour appeared ineffective. An early
reported human series by Williams and Spence at Johns
Hopkins in 1959 [10] employed durations from 24 to
72 hours, with good outcomes at both extremes.
Hypothermia: the current state
Although many models of neuroprotection in traumatic brain
injury have shown a positive correlation between hypothermia
and outcome, several studies in humans have failed to affirm
this. In a recent meta-analysis of seven clinical trials
conducted from 1993 to 2001 [14], it was concluded that
hypothermia is not beneficial in the management of severe
head injury. Those authors did, however, concede that further
studies are ‘justified and urgently needed’.
Design problems exist in both of the two new trials of
hypothermia for CA [1,2], namely potential bias (the treating
physicians were unblinded), the sample sizes were small, and
some of the treatment protocol aspects were different (such
as the time of initiation of hypothermia [in the field versus
hospital] and duration of hypothermia [12 versus 24 hours]).
Critics of those studies have expressed concerns over
several issues [3–5]: the hypothermia and normothermia
groups may not have been well matched; the sample sizes
were small; the subgroups of patients with CA analyzed were
small percentages of the total number of CAs (13–19%);
and side effects of hypothermia can be extensive.
The responses of the principal investigators to those issues
indicate that both groups were well matched, with median
Glasgow Coma Scale scores of 3 in both groups and
interquartile ranges from 3 to 4 or 5 [6]. They also point out
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Figure 1
Difference in hypothermia versus normothermia: study comparisons. Shown is the percentage favorable outcome, or survival to discharge,
compared among the two recent studies of hypothermia as treatment following cardiac arrest [1,2], a small series from 1959 (27 patients, 12
treated with hypothermia) [9], and three nonhypothermic series [20–22]. The right-most three bars are zero within the hypothermia group because
they represent studies that were not designed to test hypothermia as an intervention [20–22]. Visual comparison reveals the closeness of new data
from the two trials [1,2] with respect to the other studies [9,20–22]. *, †, ‡These studies were not hypothermic trials; rather, they are included here
to give a perspective on relative discharge statistics following cardiac arrest from other series.
0
10
20
30
40
50
60
Holzer . 2002 et al 55 39
Bernard 2002 . et al 49 26
Benson 1959 . et al 50 14
Bottinger 1999* . et al 03 4
Eisenburg 1990† . et al 02 9
Roine 1990‡ . et al 03 6
Hypothermia Normothermiathat, although the subgroup of CA in their studies was a
small percentage of the whole CA population, future studies
may show that hypothermia could confer a benefit in other
subgroups [6,7]. Finally, the two clinical trials from Europe [1]
and Australia [2] showed no statistical difference in side-
effect profiles between the normothermic and the
hypothermic groups. Potential side effects of hypothermia
such as arrhythmias, coagulopathies, infection, electrolyte
disturbance, and hypothermia-induced polyuria were
previously reported in the literature [5,11,16]. In mild
hypothermia, it appears that the incidence and severity of
side effects is diminished. For example, the development of
arrhythmia is temperature related; temperatures below 30°C
are more likely to cause serious arrhythmias such as
ventricular fibrillation [9]. Additionally, some of the
complications experienced in early studies of hypothermia
can be negated using modern intensive care monitoring and
treatment plans.
Despite the study flaws described above, outcomes show
agreement with the relative percentages presented in other
studies. In Fig. 1 the numbers of favorable outcomes from the
normothermia arms of the two trials can be seen to
approximate closely those of other studies over time. Also,
despite the small size of the samples, both studies achieved
statistical significance (Table 1).
Hypothermia: our opinion
The evidence suggests that hypothermia reduces neurologic
injury in animals and humans through several intricate
biochemical and physiologic mechanisms, most of which we
are only beginning to understand. The European [1] and
Australian [2] trials both show statistically significant and
clinically relevant improvement. Thus, we believe that the time
has come to conduct extensive, large, multicenter trials using
hypothermia to provide neurologic protection after cardiac
arrest. The trials should include broader populations of CA
patients (i.e. not limited to ventricular fibrillation arrest) and
larger study populations, should explore a quicker method of
cooling (such as intravascular cooling catheters), and should
attempt to establish an effective duration of therapy (12
versus 24 hours versus other durations).
Given the high incidence of CA and the speed with which
patients typically come to medical attention, the numbers of
patients available for recruitment should allow a reasonable
study completion time. Additionally, if, as expected, the larger
trials support the findings of the recent smaller trials, then
this will provide the impetus to examine other causes of
hypoxic/ischemic injury, such as acute ischemic stroke.
Until such larger trials are conducted, it is our opinion that
the evidence, provided in prior feasibility/safety studies as
well as in the combined European and Australian trials
reported earlier this year, supports employing mild
hypothermic therapy in the patient populations studied (those
who have suffered witnessed ventricular fibrillation arrest,
restoration of spontaneous circulation, etc.).
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